button bars forest bayes pooled summary circles
 
DCR

mCRC - 2nd line (L2) metastatic/advanced - colorectal cancer (mCRC) mCRC - 2nd line (L2)

versus BSC
durvalumab plus tremelimumab vs. BSC 1 certainty unassessable+316%
versus regorafenib
atezolizumab alone vs. regorafenib 1 -
atezolizumab plus cometinib vs. regorafenib 1 -

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons